Wegovy is the weight-loss branded version of semaglutide, developed specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. While Ozempic tops out at 2mg for diabetes management, Wegovy is titrated to 2.4mg — a higher dose that produces meaningfully greater weight loss outcomes.
FDA-approved for weight management in June 2021, Wegovy became the first GLP-1 medication specifically indicated for obesity treatment in over a decade. It is also approved to reduce the risk of cardiovascular events in adults with obesity and established cardiovascular disease — making it the first weight-loss drug with a proven heart benefit.
In the landmark STEP 1 clinical trial, participants on 2.4mg semaglutide lost an average of 14.9% of their body weight over 68 weeks — more than three times the weight loss seen with placebo. In the 2024 STEP-UP trial studying the higher 7.2mg Wegovy HD dose, participants achieved even greater results.











